Phaseline

Companies › SymBio Pharmaceuticals

SymBio Pharmaceuticals: clinical trials, targets and expected readouts

1 active drug program in 2 registered trials: 1 Phase 3, 1 Phase 2; Infectious disease; next expected readout Jan 2028.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Brincidofovir
DNA polymerase inhibitor
DNAPhase 3Adenovirus Infections; Progressive Multifocal LeukoencephalopathyJan 2028

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07387367BrincidofovirPhase 3Adenovirus InfectionsInfectious diseaseJan 2028
NCT07511049BrincidofovirPhase 2Progressive Multifocal LeukoencephalopathyInfectious diseaseDec 2029

From the company's SEC filings

Private offerings reported to the SEC (Form D)

Targets

DNA (1)

Companies with the same targets

–

Companies built like this

TCM Biotech International Vivacelle Bio Ansun Biopharma F2G Baxis Pharmaceuticals

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.